Kornimate/medical-research-clean huggingface dataset:
measuring brain tumor consistency using magnetic resonance elastography

Conditions: Brain Neoplasm

Summary: this clinical trial tests whether a new imaging technique called magnetic resonance elastography (mre) is useful in determining the consistency of brain tumors and whether this could be used to guide surgical planning and choice of approach (the type of surgery that is needed) for patients with brain tumors. comparing mre with the typical magnetic resonance imaging (mri) scan may help researchers assess the quality, reliability, and diagnostic utility of this scan when evaluating brain tumors.

primary objectives: i. examine tolerance interval of mre measurement in kilopascals (kpa) and associated distribution of percent stiff (hard) and soft tumors above the higher limit and below the lower limit. ii. through machine learning with mre and clinical/demographic factors, to identify diagnostic thresholds in separating stiff tumor from soft tumor. outline: patients undergo mre scan over 25 minutes before surgery at the time of standard of care pre-operative mri scan. on the day of surgery, the surgeon grades and records tumor consistency/stiffness during the operation and afterwards.

Eligibility criteria:
inclusion criteria: * all patients 18 years of age or older who undergo surgical resection for brain tumor at keck medical center of university of south carolina (usc) are eligible for inclusion into this study exclusion criteria: * patients who cannot tolerate mre * those ineligible for mri due to metallic implants, claustrophobia, or body habitus too large to fit in our mri machine * those not undergoing surgical resection of brain tumor * children under the age of 18, pregnant women, wards of the state, and prisoners * there will be no exclusion of patients based on gender, racial or ethnic origin
dexamethasone treatment of congenital adrenal hyperplasia

Conditions: Adrenal Hyperplasia, Congenital

Summary: the purpose of this study is to determine if dexamethasone given at night is a more effective treatment for congenital adrenal hyperplasia in young children than standard three times per day hydrocortisone. our hypothesis is that nocturnal dexamethasone will lead to more efficient suppression of the hypothalamic-pituitary-adrenal axis. we performed a cross-over trial comparing hormonal control during two 24-hour hospitalizations, one on hydrocortisone and one on nocturnal dexamethasone.

this is a phase ii clinical trial, intended to estimate the effect of instituting dexamethasone therapy in comparison to prior standard therapy. each subject provides his own baseline data. there is no control group. patients with cah who meet inclusion criteria will be admitted to the clinical research center for two 24 hour hospitalizations. adrenal hormone profiles will be measured during each hospitalization. the patient will take his or her baseline hydrocortisone regimen during one hospitalization and a new regimen consisting of a single daily nocturnal dose of dexamethasone during the second hospitalization.

Eligibility criteria:
inclusion criteria: * classic salt-wasting 21-hydroxylase deficient congenital adrenal hyperplasia * pre-pubertal children with bone ages below 8 years exclusion criteria: * age less than 2 years * patients with additional medical conditions necessitating glucocorticoid therapy. * patients on phenytoin, barbiturates, and rifampin as these medications accelerate the metabolism of glucocorticoids. * patients on ketoconazole as this medication increases the bioavailability of glucocorticoids.
strategies for teaching verbs

Conditions: Language Development Disorders; Down Syndrome; Child Language

Summary: this study is designed to evaluate whether children with down syndrome and children with typical development exhibit different levels of accuracy demonstrating novel verbs taught under three conditions: semantic cues (perform action), syntactic cues (sentence frame), and combined (syntactic and semantic cues). the participants complete an eligibility evaluation and then one verb learning session (approximately 60 minutes in length). during that verb learning session they are taught sets of words under each condition (i.e., within-subjects design) and then asked to identify and label those target words immediately after instruction.


Eligibility criteria:
inclusion criteria: * must use oral communication as their primary means of communication * must be monolingual english speakers * behaviorally able to attend for 20 minutes * children with typical development must demonstrate no more than one standard deviation below the mean on the speech and language measures exclusion criteria: * nonverbal cognitive score less than three standard deviations below the mean (standard score of 54 below) * identified hearing loss or failed hearing screening * uncorrected vision impairment * motor impairment that prevents completion of study activities * concomitant disorders (e.g., autism spectrum disorder)
efficacy and safety of propranolol versus acebutolol on the proliferative phase of infantile hemangioma

Conditions: Hemangioma

Summary: there is no effective treatment for hemangioma regardless of immediate severity. that is in this respect a orphan disease. these hemangiomas, sometimes large, will have a phase of proliferation of several months (very scary for parents) and regression over several years. the natural history is peppered with local complications (ulcers) and aesthetic and psychological sequelae (sometimes major for the child and the family). the effects of acebutolol and propranolol on the proliferative hemangiomas were discovered accidentally by two french teams (montpellier for acebutolol and bordeaux for propranolol). acebutolol and propranolol have been used for many years for the treatment of hypertension and congenital heart disease, including infants, with few side effects. the effects of acebutolol and propranolol were immediately visible with reduced volume and skin whitening of the hemangioma. in a preliminary study, acebutolol was administered to 20 patients in montpellier with big regression of hemangiomas. the aim of the study was to compare the clinical efficacy of acebutolol (10mg/kg/jour) and propranolol (3mg/kg/j) on the proliferative phase of infantile hemangioma in infants.


Eligibility criteria:
inclusion criteria: * infants under 6 months * presenting a hemangioma with the following characteristics: * subcutaneous and / or cutaneous * minimum diameter of 1.5cm on face, 5cm outside face and 3cm if it is ulcerated. * without functional impairment requiring treatment or vital corticosteroid * consent of both parents (or the person having parental authority in families) * which at least one parent is a beneficiary of a social security system. exclusion criteria: * indication of treatment with corticosteroids for an indication other than hemangioma * indication of treatment with beta-blocker for another indication that the hemangioma * infant presenting cons-indications for the administration of acebutolol or propranolol: * asthma and chronic obstructive pulmonary disease in their severe forms. * heart failure controlled by treatment. * cardiogenic shock * prinzmetal angina * bradycardia (\<80 beats / min at rest the first month \<70/minute from 1 to 6 month). * raynaud's phenomenon and peripheral arterial disorders in their severe forms. * pheochromocytoma untreated. * low blood pressure (blood pressure \<60/30 mmhg before 6 months) * hypersensitivity to acebutolol or propranolol * history of anaphylactic reaction. * treatment with amiodarone and / or calcium channel blockers. * congenital heart disease outside inter auricular communication (cia) or inter ventricular communication (civ) insignificant

Keywords: hemangioma beta-blocker acebutolol propranolol randomized controlled trial infants
idronoxil suppository combine with radiotherapy for metastatic prostate cancer

Conditions: Metastatic Castrate- Resistant Prostate Cancer

Summary: the aim of the study is to determine the toxicity of idronoxil (nox66) when used in combination with palliative radiotherapy for metastatic prostate cancer

who is it for? patient may be eligible for this study if they have late stage metastatic prostate cancer which is castrate resistant and have metastatic lesions that are suitable for radiotherapy. study details there are two groups of patients in this study and no randomisation. the two groups will have two different doses of idronoxil (nox66), representing a 2-step dose escalation. both groups receive the same standard radiotherapy dose. group 1 will receive the lower dose (400 mg) of idronoxil suppository daily and group 2 800 mg daily. recruitment into group 2 will only commence once all group 1 patients have completed the 13-day treatment course of idronoxil suppository without excessive unexpected toxicity. the total treatment duration will be 13-15 days for both groups depends on whether radiotherapy is given on consecutive days or over the weekend. day 0: commence idronoxil (nox66) days 1-5: 1 or 2 lesions will receive 20 gy (radiotherapy dose unit) radiotherapy in 5 daily fractionated doses and continue daily nox66 day 6-12: continue nox66 (the duration of nox66 will be 13-15 days depends on whether radiotherapy is given on consecutive days or over the weekend). both groups will have prostate-specific membrane antigen positron emission tomography (psma-pet) scans before starting treatment and three months after the last fraction of radiotherapy to assess treatment response.

Eligibility criteria:
inclusion criteria: * confirmed metastatic prostate cancer that is castrate-resistant. * 2-3 lesions suitable for radiotherapy. * ecog performance status 0-2. * adequate bone marrow, hepatic and renal function * at least 4 weeks must have elapsed prior to commencement of idronoxil treatment since prior chemotherapy, investigational drug or biologic therapy exclusion criteria: * chemotherapy regimens with delayed toxicity within the last 4 weeks. * any situation where the use of suppository therapy is contra-indicated or impractical(eg. chronic diarrhoea, colostomy, ulcerative colitis). * no concurrent systemic chemotherapy or biologic therapy is allowed. * psychiatric disorder or social or geographic situation that would preclude study participation. * patient unable to provide consent
management of padis in emergency intensive care unit

Conditions: Pain; Agitation, Emergence; Delirium; Critical Illness

Summary: investigate the prevalence of padis in eicu, as well as the awareness and clinical implementation status of medical staff towards padis. the investigators conducted a multicenter cross-sectional survey in mainland china, including a one-day point prevalence investigation and a questionnaire survey. the inclusion criteria encompassed all adult patients admitted to the participating emergency department intensive care units (edicus) during the on-site screening, while exclusion criteria comprised patients aged less than 18 years, edicu stays duration less than 24 hours before the screening, and participation in other concurrent trials. hospital and nursing records from the 24 hours preceding enrollment were examined to document the assessment rate of pain, agitation-sedation, and delirium. physicians and nurses on duty 24 hours before the patients\&#39; enrollment was invited to complete the questionnaire survey regarding the icu profiles, professional expertise, assessment and treatment of pad, early mobilization, and sleep improvement practices.


Eligibility criteria:
inclusion criteria: * all patients admitted to the participating edicu during the on-site investigation exclusion criteria: * age less than 18 years; * edicu stay duration before the screening was less than 24 hours * enrollment in other concurrent trials.

Keywords: emergency department intensive care units prevalence survey practices
point-of-care monitoring of antibiotic concentration in blood with uv-vis absorption spectroscopy

Conditions: Sepsis; Infection, Bacterial

Summary: this prospective clinical study will investigate if antibiotic concentrations in patients with severe infections can be monitored by the uv-vis spectroscopy.

early and correct antibiotic treatment has a fundamental effect on survival in severe infections, and to prevent resistance development. however, it is unclear if this is achieved in severely ill patients with severe infections. underdosing of antibiotics leads to lack of effect against bacteria and selection of multi-resistant strains. overdosing of antibiotics increases the risk of toxicity and poses a threat to the environment. currently there is no method for rapid or bedside determination of antibiotic concentration in routine health care. pharmacolog ab, an uppsala med-tech company, has developed a technology and a product druglog® based on absorption spectroscopy in ultraviolet - visible (uv-vis) frequencies that can measure the concentration of antibiotics. the goal of this project is to investigate if antibiotic concentrations in patients could be monitored by the uv-vis spectroscopy. in a prospective observational study, blood samples from 100 patients with severe infections treated with cefotaxime, piperacillin/tazobactam or meropenem will be measured by uv-vis spectroscopy as well as with the golden standard, high-performance liquid chromatography-mass spectrometry (hplc-ms) at klinisk farmakologi, huddinge hospital, stockholm. after informed consent, samples will be taken prior to antibiotic treatment and three times thereafter. demographic and clinical data will be registered.

Eligibility criteria:
inclusion criteria: * more than 18 years old * suspected infection where treatment with cefotaxime, piperacillin/tazobactam or meropenem is prescribed exclusion criteria: * pregnancy * intermittent haemodialysis * patient with limited treatment decision

Keywords: meropenem cefotaxime piperacillin/tazobactam drug monitoring antibiotics
safety and feasibility study of autologous progenitor cell transplantation in diabetic neuropathy

Conditions: Diabetic Neuropathies

Summary: treatment of patients with diabetic neuropathy by intraarterial progenitor cell transplantation.

goal is: stimulation of angiogenesis and induction of vasa nervorum in order to improve nerve function

Eligibility criteria:
inclusion criteria: * patients with distal symmetrical diabetic neuropathy of the legs * type 1 or type 2 diabetes * stable glucose control over last 3 months (hba1c \<7.5) * written informed consent exclusion criteria: * patients with peripheral arterial disease (abi \<0.9) * neuropathy of other origin * myopathy * asymmetrical neuropathy * active infection oder fever * chronic inflammatory disease (z.b m. crohn, rheumatoid arthritis) * hiv or hepatitis * neoplastic disease without complete remission within last 5 y * stroke or myocardial infarction within last 3 months * renal failure (creatinine \> 2 mg/dl) * liver disease (got \> 2 upper limit or spontaneous inr \> 1,5). * anemia (hemoglobine \< 8.5 mg/dl) * platelets \<100.000/µl * hba1c \>7,5 % * allergies to aspirin, clopidogrel, heparin * bleeding disorder * surgery or trauma within the last 2 months * pregnancy * mental retardation * participation in another study within 30 days

Keywords: patients with symmetric peripheral diabetic neuropathy
pharmacokinetics (pk), pharmacodynamics (pd) and safety study of mt-1303 in subjects with crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to evaluate pk, pd and safety of a single oral dose of mt-1303 in subjects with crohn's disease.

this is a phase i, open-label, non-randomised, multicenter single-dose study to evaluate pk, pd, and safety of a single oral dose of mt-1303 in subjects with moderate to severe active crohn's disease (ileal and ileo-colonic type).

Eligibility criteria:
inclusion criteria: * subjects who were diagnosed as crohn's disease * subjects who were confirmed as ileal or ileo-colonic type by image inspection. * disease severity determined as either "moderate" or "severe" exclusion criteria: * present or past history of gastrointestinal surgery which may have impact on drug absorption * subjects with stenosis or fistula in small intestine or colon

Keywords: crohn's disease
ecigs, inflammation and oxidative stress

Conditions: E-cigarettes, Oxidative Stress, Inflammation

Summary: randomized controlled trial of acute use of electronic cigarette effect on oxidative stress and inflammation.

participants will have an acute e-cig exposure on 2 occasions 1) e-cigarette 2) sham e-cig (empty e-cig) control. blood will be collected before and after e-cig use and analyzed for biomarkers of inflammation and oxidative stress.

Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * cardiac disease respiratory disease diabetes
beneficial effects of an integrated program of multicomponent physical exercise. cohort study

Conditions: Frailty; Geriatric Syndromes; Functional Recovery

Summary: the study has been designed to analyze the possible positive effects of a multicomponent physical exercise program monitored with an integrated electronic device system in dwelling-community frailty older adults. the study will assess changes in physical, nutritional, cognitive, and psychological aspects after program finishes at six months. information will be collected by researchers at baseline, monthly and after study finishes.

the aging process is associated with physiological changes that determine a decrease in functional reserve and limit the ability to respond to external factors. likewise, aging is associated with a deterioration of the regulatory processes that maintain the functional integration of the different organs and systems. a direct consequence of this phenomenon is the atypical presentation of highly prevalent diseases in the elderly. this atypical presentation of diseases in the elderly is responsible for the so-called geriatric syndromes, considered as specific nosological entities with a high frequency of presentation in the elderly, being included within the prevention, diagnosis and treatment strategies of geriatric medicine. these syndromes can generate greater morbidity and consequences, sometimes more serious than the disease that produces them. its systematic detection should be included in the anamnesis of the clinical history of the elderly. geriatric syndromes are a group of conditions usually caused by the conjunction of diseases with a high prevalence in the elderly and which are the frequent origin of functional or social disability in the population. they are the manifestation of many diseases, but they are also the beginning of many other problems that we must take into account from their detection to establish a good prevention of them. the hypothesis of this work is that in frail and pre-frail older adults who participate in an integrated program of multicomponent physical exercise tutored by means of an app will improve their functional situation and reverse their diagnoses of pre and frailty.

Eligibility criteria:
inclusion criteria: * frailty * informed consent signature exclusion criteria: * life expectancy less than 6 months * acute ischemic coronariopathy event during the last three months * active cancer treatment (chemoteraphy or radiotherapy) during the last three months * major surgery during the last six months

Keywords: older adults frailty geriatric assessment geriatric syndromes multicomponent exercise program
brugada syndrome and artificial intelligence applications to diagnosis

Conditions: Brugada Syndrome 1

Summary: aim of the project is the development of an integrated platform, based on machine learning and omic techniques, able to support physicians in as much as possible accurate diagnosis of type 1 brugada syndrome (brs).

the aim of braid project is to integrate classic clinical guidelines for brugada syndrome 1 diagnosis evaluation with innovative information and communication technologies and omic approaches, generating new diagnostic strategies in cardiovascular precision medicine of this disease.

Eligibility criteria:
inclusion criteria: * brugada patients: patients with brugada syndrome 1 spontaneous or induced by the ajmaline test; patients with non-diagnostic electrocardiographic pattern for brugada syndrome 1 or negative in the presence of high clinical suspicion (family history for brugada syndrome, patients who survived cardiac arrest without organic heart disease) * control patients: patients with frequent premature ventricular complex and normal left and right ventricular function; patients with suspected brugada syndrome 1 not confirmed by ajmaline test exclusion criteria: * organic heart disease or diseases interfering with protocol completion * lack of signed informed consent * pregnancy * acute coronary artery disease, heart failure in the previous 3 months * severe renal or liver failure
immunogenicity and safety of commercially available vaccines against sars-cov-2 (covid-19) in patients with hematologic malignancies

Conditions: Monoclonal B-Cell Lymphocytosis; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; B-cell Non Hodgkin Lymphoma; Hodgkin Lymphoma

Summary: d1. primary objective: 1. determine the immunogenicity of fda approved covid-19 vaccination in patients with hematologic malignancies d2. secondary objectives: 1. assess the safety of fda approved covid-19 vaccination in patients with hematologic malignancies 2. analyze the kinetics of immunogenic response over time after receipt of the covid-19 vaccination 3. compare the immunogenicity of different covid-19 vaccinations that will be approved by the fda 4. analyze advanced flow immunophenotyping of innate and adaptive immune blood cells in all participants and correlate with response to vaccination


Eligibility criteria:
inclusion criteria: 1. patients must not have received any prior covid-19 vaccination 2. patients must have any one of the following diagnosis: a. monoclonal b-cell lymphocytosis b. chronic lymphocytic leukemia/small lymphocytic lymphoma c. b-cell non-hodgkin's lymphoma: i. follicular lymphoma ii. mantle cell lymphoma iii. diffuse large b-cell lymphoma iv. marginal zone lymphoma v. burkitt lymphoma vi. double hit/triple hit lymphoma vii. lymphoplasmacytic lymphoma/waldenstrom's macroglobulinemia d. hodgkin lymphoma exclusion criteria: 1. receipt of any vaccination (e.g., influenza, recombinant zoster) 2 weeks prior to registration 2. prior chemotherapy, immunotherapy or oral agent therapy that was completed \>12 months prior to enrollment. note: patients who are on oral agents for the treatment of their underlying malignancy will be allowed. some of these medication classes include bruton tyrosine kinase inhibitor (btki), bcl2 antagonists, pi3 kinase inhibitors, immunomodulatory agents, among others. please contact the principal investigator for any clarification about these medications.

Keywords: lymphoma covid-19 vaccine cll